PHARMAC performance 2014/2015 Q2
Performance data to 31 December 2014
Our impacts: Impact on access to medicines
In the three months to 31 December 2014, PHARMAC added 9 pharmaceuticals to the Pharmaceutical Schedule, and widened access to 16 others so they are accessible to more patients. We estimate that these decisions will lead to $9.0 million of gross expenditure and at least 10,930 patients receiving these medicines in the 2014/15 financial year, the first full year following the medicines being funded.
From 1 July 2013, the Hospital Medicines List (HML) came into effect. In the second quarter, PHARMAC added two new listings and widened access to one pharmaceutical listed on the HML. Additional expenditure and savings were made through various tender and NPPA decisions.
Output Class 1: Decision-making
Measure: All funding decisions are supported by evidence and made using PHARMAC’s nine decision criteria.
Status: On track. All PHARMAC funding decision papers (to PHARMAC Board or its delegate) include information on how the decision aligns with the nine decision criteria.
Measure: Decisions on more than 90% of line items (excluding bids held open while awaiting Medsafe registration) will be made within 6 months of the tender closing.
Status: On track. The Tender closed on 18 December 2014. The evaluation process has begun and the target will be met in late January 2015 once provisional preferred suppliers are identified.
Measure: Hospital medical devices gross savings five-year NPV at least $4.74m.
Status: On track. Hospital medical devices gross savings five-year NPV at least $5.1m. Five year gross cumulative value estimated at $11.1m.
Measure: New investments made in hospital pharmaceuticals within financial limits agreed with DHB. Funding decisions supported by evidence and made using PHARMAC’s decision-making approach.
Status: On track. Savings and investments in hospital medicines being tracked and all PHARMAC funding decision papers (to PHARMAC Board or its delegate) include information on how the decision aligns with the nine decision criteria.
Output Class 2: Influencing medicines use
Measure: Amount of campaign materials distributed is greater than previous year.
Status: Not on track: In the first half of 2014/15, there were 364 orders for campaign materials, with an average of 2.7 different ‘products’ per order (total orders in 2013/14 were 1,056 with an average of 2.6 products per order). This reflects an ongoing shift away from paper to electronic resources.
A full year summary of distribution, including comparison with the previous year, will be provided at year-end.
Measure: Surveys of attendees show at least 90% of surveyed attendees rate their satisfaction with the Seminars at least 4 out of 5.
Status: On track: PHARMAC hosted four seminars in the period 1 October to 31 December 2014. Feedback from 94% of respondents rated the seminars at least 4 out of 5.
Measure: RFP completed and six presentations delivered through contracted partner to four different provider groups.
Status: On track: Memoranda of Agreement (MoA) signed with two Whānau Ora Collectives and a third undergoing review which will enable programme delivery from 2015.
The RFP process was withdrawn and superseded by Whanau Ora Collectives and Māori Pharmacists’ Association MoA for future HRPHOW delivery.
Measure: Respond to low medicine stock reports, communicate effectively and take action as necessary to ensure patient needs for medicines are met.
Status: On track: There were 27 new low stock reports in the second quarter, 12 of which have been resolved. At the end of the second quarter PHARMAC was monitoring or actively managing 35 low stock reports.
Output Class 3: Providing policy advice and support
Measure: An average survey score of at least 4.5 in each area.
Status: This survey is completed annually at year-end and reported in the final quarter report.
Measure: All fund use is in accordance with PHARMAC policy.
Status: On track. A payment of $8 million was made to DHBs in relation to Combined Pharmaceuticals on 22 December 2014, which covered the remaining cash payable for 2013/14 rebates.
Last updated: 4 February 2016